Compare UNTY & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UNTY | RCKT |
|---|---|---|
| Founded | 1991 | 1999 |
| Country | United States | United States |
| Employees | N/A | 202 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 523.6M | 534.2M |
| IPO Year | 2014 | N/A |
| Metric | UNTY | RCKT |
|---|---|---|
| Price | $49.00 | $4.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 14 |
| Target Price | ★ $65.00 | $29.65 |
| AVG Volume (30 Days) | 29.9K | ★ 2.7M |
| Earning Date | 04-10-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.22% | N/A |
| EPS Growth | ★ 39.66 | N/A |
| EPS | ★ 5.67 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.57 | N/A |
| Revenue Next Year | $8.52 | $97.68 |
| P/E Ratio | $8.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.65 | $2.19 |
| 52 Week High | $57.30 | $8.80 |
| Indicator | UNTY | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 30.28 | 50.69 |
| Support Level | $46.88 | $2.99 |
| Resistance Level | $50.16 | $5.39 |
| Average True Range (ATR) | 1.38 | 0.38 |
| MACD | -0.27 | -0.06 |
| Stochastic Oscillator | 4.14 | 22.09 |
Unity Bancorp Inc is a bank holding company that serves as a holding company for Unity Bank. It conducts a traditional and community-oriented commercial banking business and offers services, including personal and business checking accounts, time deposits, money market accounts, regular savings accounts, and others. The company structures its specific services and charges in a manner designed to attract the business of small and medium-sized businesses and professional communities, as well as individuals residing, working, and shopping in its service area. The company engages in a wide range of lending activities and offers commercial, Small Business Administration, consumer, mortgage, home equity, and personal loans.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.